Browse > Article

Gemcitabine Plus Vinorelbine as Second-line Chemotherapy of the Patients of Previously Treated Non-small Cell lung Cancer: Phase II Trial  

Jang, Pil Soon (Department of Internal Medicine, Chungnam National University Hospital, Cancer Research Institute)
Kang, Hyun Mo (Department of Internal Medicine, Chungnam National University Hospital, Cancer Research Institute)
Lee, Jeong Eun (Department of Internal Medicine, Chungnam National University Hospital, Cancer Research Institute)
Kwon, Seon Jung (Department of Internal Medicine, Chungnam National University Hospital, Cancer Research Institute)
An, Jin Young (Department of Internal Medicine, Chungnam National University Hospital, Cancer Research Institute)
Lee, Yun Sun (Department of Internal Medicine, Chungnam National University Hospital, Cancer Research Institute)
Jeong, Sung Soo (Department of Internal Medicine, Chungnam National University Hospital, Cancer Research Institute)
Kim, Ju Ock (Department of Internal Medicine, Chungnam National University Hospital, Cancer Research Institute)
Kim, Sun Young (Department of Internal Medicine, Chungnam National University Hospital, Cancer Research Institute)
Publication Information
Tuberculosis and Respiratory Diseases / v.58, no.4, 2005 , pp. 344-351 More about this Journal
Abstract
Background : Both gemcitabine and vinorelbine are effective anticancer drugs with mild toxicity on non-small cell lung cancer, and monotherapy of these drugs are effective as a second-line chemotherapy. The aim of this trial was to assess the response and toxicity of a combination of gemcitabine and vinorelbine in patients of previously treated for non-small cell lung cancer. Materials and Methods : 24 patients, initial stage III A/B,IV and previously treated with platinium and taxane based regimens, were enrolled from June 2000 to March 2004. The regimens consisted of vinorelbine $25mg/m^2$ followed by an infusion of gemcitabine $1000mg/m^2$ on day 1 and day 8 every three weeks. This course was repeated more than twice. Results : Twenty-four patients were analyzed for the response, survival rate, and toxicities. The overall response was 17% with a complete remission rate of 4%. The median time-to progression (TTP) was 3.1 months (95%, CI 1-10months), and the survival time was 8.2 months (95%, CI 1-23 months). The grade 3/4 toxicities encountered were neutropenia (12.5%), anemia (0%), thrombocytopenia (0%). Non-hematological 3/4 toxicities were not observed. Conclusion : A combination of gemcitabine and vinorelbine in patients previously treated for non-small cell lung cancer provides a relatively good response rate, and a low toxicity profile. However, further study will be needed to confirm its effectiveness.
Keywords
Advanced non-small cell lung cancer; Second-line chemotherapy; Gemcitabine; Vinorelbine;
Citations & Related Records

Times Cited By SCOPUS : 1
연도 인용수 순위
1 Johnson SA, Harper P, Hortobagyi GN, Pouillart P. Vinorelbine: an overview. Cancer Treat Rev 1996;22:127-42   DOI   ScienceOn
2 Gatzemeier U, Heckmayr M, Neuhauss R, Schluter I, Pawel JV, Wagner H, et al. Phase II trial of paclitaxel for treatment of advanced inoperable nonsmall cell lung cancer. Lung Cacner 1995;12:S101-6
3 Laack E, Mende T, Benk J, Chemaissani A, Scholtze J, Lorenz C, et al. Gemcitabine and vinorelbine as first-line therapy for non-small cell lung cancer: a phase II trial. Eur J Cancer 2001;37:583-90   DOI   ScienceOn
4 Laack E, Dickgreber N, Muller T, Knuth A, Benk J, Lorenz C, et al. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabin, vinorelbine and cisplatin in the treatment of advanced non-small cell lung cancer. J Clin Oncol 2004;22:2348-56   DOI   ScienceOn
5 Komas C, Tsavaris N, Panopoulos C, Vadiaka M, Stavroyianni N, Kourelis T, et al. Gemcitabine and vinorelbine as second-line therapy in non-small cell lung cancer after prior treatment with taxane+pla-tinum-based regimens. Eur J Cancer 2001;37:972-8   DOI   ScienceOn
6 Androulakis N, Kouroussis C, Kakolyris S, Tzannes S, Papadakis E, Papadimitriou C, et al. Salvage treatment with paclitaxel and gemcitabine for patients with non-small cell lung cancer after cisplatin or docetaxel-based chemotherapy: a multicenter phase II trial. Ann Oncol 1998;9:1127-30   DOI   ScienceOn
7 Hotton KM, Kim K, Larson ML. Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer pre-viously treated with platinumbased chemotherapy. Proc Am Soc Clin Oncol 1999;18:509
8 Francis PA, Rigas JR, Kris MG, Pisters KM, Orazem JP, Woolley KJ, et al. Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 1994;12:1232-7   DOI
9 Park YH, Lee JC, Ryoo BY, Kim CH, Kim HT. Gemcitabine and vinorelbine as second-line therapy for non-small cell lung cancer after treatment with paclitaxel plus platinum. Jpn J Clin Oncol 2004;34:245-9   DOI   ScienceOn
10 Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA. Efficacy and safety profile of gemcitabine in non-small cell lung cancer: a phase II study. J Clin Oncol 1994;12:1535-40   DOI
11 Androulakis N, Papadakis E, Bania E. Second-line treatment with docetaxel and gemcitabine in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1999;18:491
12 Reddy GR, Gandara DR, Edelman MJ. Gemcitabine in platinum treated non-small cell lung cancer. Proc Am Soc Clin Oncol 1999;18:521
13 Nakanishi Y, Takayama K, Takano K, Inoue K, Osaki S, Wataya H, et al. Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer. Am J Clin Oncol 1999;22:399-402   DOI   ScienceOn
14 Camps C, Martinez EN, Jaime AB. Second-line treat- ment with gemcitabine and vinorelbine in non-small cell lung cancer cisplatin failures: a pilot study. Lung Cancer 2000;27:47-53   DOI   ScienceOn
15 Kim SY, Kim GH. Rescent advances in lung cancer chemotherapy. Tuberc Respir Dis 2000;49:533-45   DOI
16 Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, et al. Comparison of survival and quality of life in advanced non-small cell lung cancer patients versus etoposide with cisplatin. J Clin Oncol 2000;18:623-31   DOI
17 Fuks JZ, Egorin MJ, Aisner J, van Echo DA, Ostrow S, Bachur NR, et al. Therapeutic efficacy and pharmacokinetics of vindesine and of vindesin-cisplatin in previously treated patients with non-small cell lung cancer. Cancer Chemother Pharmacol 1983;10:104-8   DOI   ScienceOn
18 Ruckdeschel J, Wagner HW. Second-line chemotherapy for resistant, metastatic non-small cell lung cancer:the role of taxol. Proc Am Soc Clin Oncol 1994;13:357
19 Krajnik G, Wein W, Greil R, Marhold F, Mohn-Staudner A, Kummer F, et al. Vinorelbine/gemcitabine in advanced non-small cell lung cancer: a phase I trial. Eur J Cancer 1998;34:1977-80   DOI   ScienceOn
20 Depierre A, Lemarie E, Dabouis G, Garnier G, Jacoulet P, Dalphin JC. A phase II study of vinorelbine in the treatment of non-small cell lung cancer. Am J Clin Oncol 1991;14:115-9   DOI   ScienceOn
21 Kosmidis P, Mylonskis N, Fountzilas G, Samantas E, Athanasiadis A, Skarlos D. Paclitaxel and carboplatin in inoperable non-small cell lung cancer. Semin Oncol 1996;23:68-70
22 van Putten JW, Baas P, Codrington H, Kwa HB, Muller M, Aaronson N, et al. Activity of single-agent gemcitabine as seconde-line treatment after previous chemotherapy or radiotherapy in advanced non-small cell lung cancer. Lung Cancer 2001;33:289-98   DOI   PUBMED   ScienceOn
23 Hainsworth JD, Thompson DS, Greco FA. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small cell lung cancer. J Clin Oncol 1995;13:1609-14   DOI
24 Hainsworth JD, Burris HA 3rd, Litchy S, Erland JB, Hon JK, Brierre JE, et al. Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients: a minnie pearl cancer research network phase II trial. Cancer 2000;88:1353-8   DOI   PUBMED   ScienceOn
25 Lorusso V, Carpagnano F, Frasci G, Panza N, de Rienzo G, Cisternino ML, et al. Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small cell lung cancer. J Clin Oncol 2000;18:405-11   DOI
26 Gatzemeier U, Shepherd FA, le Chevalier T, Weynants P, Cottier B, Groen HJ, et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 1996;32A:243-8
27 Kim YJ, Sohn JH, Kim C, Kim YT, Kim HJ, Ahn B, et al. Phase II study of gemcitabine and vinorelbine as second-line chemotherapy in non-small cell lung cancer. Cancer Res Trea 2003;35:294-8   DOI
28 Green MR. Gemcitabine safety overview. Semin Oncol 1996;23:32-5
29 Furuse K, Kubuto K, Kawahara M, Ogawara M, Kinuwaki E, Motomiya M, et al. A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Lung Cancer 1994;11:385-91   DOI   ScienceOn
30 le Chevalier T, Brisgard D, Douillard JY, Pujol JL, Alberola V, Monnier A, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vindesine alone in advanced non-small cell lung cancer. J Clin Oncol 1994;12:360-7   DOI
31 Sandler A, Ettinfer DS. Gemcitabine: single agent and combination therapy in non-small cell lung cancer. Oncologist 1999;4:241-51
32 Pronzato A, Landucci M, Vaira F, Vigani A, Bertelli G. Failure of vinorelbine to produce responses in prereated non-small cell lung cancer patients. Anti-cancer Res 1994;14:1413-5
33 Socinski MA, Steagall A, Gillenwater H. Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: report of a phase II trial. Cancer Invest 1999;17:181-8   DOI   ScienceOn
34 Camps C, Martinez EN, Jaime AB. Second-line treatment with gemcitabine and vinorelbine in non-small cell lung cancer cisplatin failures: a pilot study. Lung Cancer 2000;27:47-53   DOI   ScienceOn
35 Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, et al. Paclitaxel and carboplatin in combination in the treatment of nonsmall cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995;13:1860-70   DOI
36 Crio L, Mosconi AM, Scagliotti G, Selvaggi G, Bovello S, Rinaldi M, et al. Gemcitabine as secondline treatment for advanced non-small cell lung cancer: a phase II study. J Clin Oncol 1999;17:2081-5   DOI
37 Herbst RS, Khuri FR, Jung M. Phase II study of combination weekly gemcitabine and vinorelbine in patients with previously treated non-small cell lung cancer. Proc Am Soc Clin Oncol 1999;18:462a
38 Chang AY, DeVore R, Johnson D. Pilot study of vinorelbine and paclitaxel in patients with refractory non-small cell lung cancer. Semin Oncol 1996;23:19-21
39 Crino L, Mosconi AM, Scagliotti G, Selvaggi G, Novello S, Rinaldi M, et al. Gemcitabine as second-line treatment for advanced non-small cell lung cancer: a phase II trial. J Clin Oncol 1999;17:2081-5   DOI   PUBMED
40 Chen YM, Perng RP, Lee CS, Lin WC, Tsai CM, Whang-Peng J. Phase II study of gemcitabine and vinorelbine combination therapy in patients with nonsmall cell lung cancer not responding to previous chemotherapy. Am J Clin Oncol 2003;26:567-70   DOI   ScienceOn